Novo Nordisk said Friday it settled two lawsuits against two businesses claiming to offer compounded versions of its blockbuster drugs Ozempic and Wegovy. The drugmaker has filed a total of 12 lawsuits against clinics, med spas and compounding pharmacies in the U.S. that claim to offer semaglutide, the active ingredient in Ozempic and Wegovy.
They are also permanently banned from using any Novo Nordisk trademarks or logos in their products as well as any 'misleading' advertising, the drugmaker said. Both businesses will be given a year to make the changes. The settlements come as states have been cracking down on compounded versions of the drug, which they say may contain other ingredients that are not approved by the FDA.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: